Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study
Benjamin A. Derman, Ankit Kansagra, Jeffrey Zonder, Andrew T. Stefka, David L. Grinblatt, Larry D. Anderson, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major, Andrew Kin, Ken Jiang, Theodore Karrison, Jagoda Jasielec, Andrzej J. Jakubowiak
Dive into the research topics of 'Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study'. Together they form a unique fingerprint.